

# Annual prescribing report 2018-2019



**AWTTC**  
All Wales Therapeutics  
& Toxicology Centre

This report has been developed by:



**WAPSU**  
Welsh Analytical  
Prescribing Support Unit

## Hywel Dda

### KEY

- Aneurin Bevan
- + Cardiff and Vale
- ◆ Hywel Dda
- ✕ Swansea Bay
- Betsi Cadwaladr
- ★ Cwm Taf Morgannwg
- ▲ Powys



This logo is displayed alongside sections of the report where further data is available on the Server for Prescribing Information Reporting and Analysis (SPIRA). Find out more at [awttc.org/spira](http://awttc.org/spira)

## Primary care


## Opioid burden

*New National Prescribing Indicator for 2019-2020*




Opioids have well established side effects and repeated administration may cause tolerance and dependence. The aim of this measure is to encourage the appropriate use and review of opioids in primary care, minimising the potential for dependence, diversion, misuse and adverse drug reactions.

**Opioid burden (ADQs per 1,000 patients) - quarterly trend up to March 2019**



**Opioid burden (ADQs per 1,000 patients) - Locality data - Financial year 2018-2019**



When compared with the previous year, Hywel Dda's performance **IMPROVED**

Opioid burden decreased by **2.3%** in 2018-2019



Out of the 7 health boards, Hywel Dda is ranked:

% change from last year : **2<sup>nd</sup>**

Current overall performance : **6<sup>th</sup>**

## GLOSSARY

**ADQs** – **average daily quantity** – a measure of prescribing volume based upon prescribing behaviour in England. It represents the assumed average maintenance dose per day for a medicine used for its main indication in adults. ADQ is not a recommended dose but an analytical unit to compare prescribing activity.

**DDDs** – **defined daily dose** – a unit of measurement developed by the World Health Organization whereby each medicine is assigned a value within its recognised dosage range. The value is the assumed average maintenance dose per day for a medicine when used for its main indication in adults. A medicine can have different DDDs depending on the route of administration.

**STAR-PU**s – **specific therapeutic group age-sex related prescribing units** – designed to measure prescribing weighted for age and sex of patients. There are differences in the age and sex of patients for whom medicines in specific therapeutic groups are usually prescribed. To make such comparisons, STAR-PU have been developed based on costs of prescribing or items within therapeutic groups.


## Primary care

## Gabapentin and pregabalin




Both gabapentin and pregabalin have the propensity to cause depression of the central nervous system, and when used in combination with other depressants they can cause drowsiness, sedation, respiratory failure and death. The aim of this measure is to encourage the appropriate use and review of gabapentin and pregabalin in primary care, minimising the potential for dependence, diversion, misuse and adverse drug reactions.

**Gabapentin and pregabalin (DDD's per 1,000 patients) - quarterly trend up to March 2019**



**Gabapentin and pregabalin (DDD's per 1,000 patients) - Locality data - Financial year 2018-2019**



When compared with the previous year, Hywel Dda's performance **DETERIORATED**

Gabapentin and pregabalin prescribing increased by **5.2%** in 2018-2019



Out of the 7 health boards, Hywel Dda is ranked:

% change from last year : **4<sup>th</sup>**

Current overall performance : **4<sup>th</sup>**


## Primary care

## Total antibiotic prescribing




The widespread and often excessive use of antimicrobials is one of the main factors contributing to the increasing emergence of antimicrobial resistance. The aim of this measure is to encourage the appropriate prescribing of all antibiotics in primary care.

**Total antibiotic prescribing (items per 1,000 STAR-PU's) - quarterly trend up to March 2019**



**Total antibiotic prescribing (items per 1,000 STAR-PU's) - Locality data - Financial year 2018-2019**



When compared with the previous year, Hywel Dda's performance **IMPROVED**

Total antibiotic prescribing decreased by **7.2%** in 2018-2019



Out of the 7 health boards, Hywel Dda is ranked:


% change from last year : **4<sup>th</sup>**

Current overall performance : **5<sup>th</sup>**




The use of the broad spectrum antibiotics known as 4C antimicrobials (co-amoxiclav, cephalosporins, clindamycin and fluoroquinolones) when narrow spectrum antibiotics remain effective increases the risk of healthcare associated infections (e.g. *Clostridioides difficile*, methicillin-resistant *Staphylococcus aureus* and resistant urinary tract infections). The aim of this measure is to reduce variation and overall prescribing of 4C antimicrobials in primary care.

4C antimicrobial prescribing (items per 1,000 patients) - quarterly trend up to March 2019



4C antimicrobial prescribing (items per 1,000 patients) - Locality data - Financial year 2018-2019



When compared with the previous year, Hywel Dda's performance **IMPROVED**

4C antimicrobial prescribing decreased by **8.8%** in 2018-2019



Out of the 7 health boards, Hywel Dda is ranked:


% change from last year : **3<sup>rd</sup>**

Current overall performance : **6<sup>th</sup>**



A series of 'Low Priority for Funding' papers endorsed by the All Wales Medicines Strategy Group recommend decreased prescribing of a range of items considered as not suitable for routine prescribing; whether they are items of low clinical effectiveness or items where more cost-effective alternatives are available. The data below displays the money saved (per 1,000 patients) due to reduced spend on items listed within these papers.

Differences in spend (£ per 1,000 patients) between financial years 2017-2018 and 2018-2019



Hywel Dda achieved a saving of **17.9%** in 2018-2019

Out of the 7 health boards, Hywel Dda is ranked:


% reduction in spend in 2018-19 : **5<sup>th</sup>**

total spend per 1,000 patients : **7<sup>th</sup>**




A biosimilar medicine is a biological medicine that is developed to be highly similar and clinically equivalent to an existing biological medicine. The aim of this measure is to increase the appropriate use of cost-efficient biological medicines, including biosimilar medicines.

**Biosimilar prescribing (as a % of total biologic)**



**Biosimilar usage in Hywel Dda (as a % of total biologic) - quarterly trend up to March 2019**



**Please note:** These data are extracted from the Medusa Data Warehouse which has a central mapping of individual items. This is reviewed on a regular basis and therefore differences may exist between various data sets.

When compared with the previous year, Hywel Dda's performance **IMPROVED** ↑  
Biosimilar prescribing (as a % of total biologic) increased by **28.3%** in 2018-2019

Out of the 6 health boards\*, Hywel Dda is ranked:

% change from last year : **4<sup>th</sup>** Current overall performance : **2<sup>nd</sup>**


\*Powys is not included in this measure.

## Access to medicines


## New Treatment Fund

The New Treatment Fund requires the seven health boards to make recommended medicines available as soon as is reasonably practicable and certainly within 60 days of AWMMSG/NICE approval. The data below displays the proportion of medicines made available on formulary within 60 days and the average time (in days) until their inclusion, following AWMMSG/NICE approval.

**Percentage of medicines on formulary within 60 days**



**Average time (days) to inclusion of medicines on formulary**



Out of the 7 health boards, Hywel Dda is ranked:

% of medicines on formulary within 60 days : **1<sup>st</sup> (joint)** in 2018-2019

Average time to inclusion of medicines on formulary : **5<sup>th</sup>** in 2018-2019